Safety, Tolerability and Preliminary Efficacy of 161Tb-LNC1011 (PSMA Radioligand) in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT07381582 · clinicaltrials.gov ↗
EARLY_PHASE1
Phase
NOT_YET_RECRUITING
Status
15
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Peking Union Medical College Hospital

Collaborators